Literature DB >> 19441089

Gene expression meta-analysis identifies chromosomal regions involved in ovarian cancer survival.

Mads Thomassen1, Kirsten M Jochumsen, Ole Mogensen, Qihua Tan, Torben A Kruse.   

Abstract

Ovarian cancer cells exhibit complex karyotypic alterations causing deregulation of numerous genes. Some of these genes are probably causal for cancer formation and local growth, whereas others are causal for metastasis and recurrence. By using publicly available data sets, we have investigated the relation of gene expression and chromosomal position to identify chromosomal regions of importance for early recurrence of ovarian cancer. By use of *Gene Set Enrichment Analysis*, we have ranked chromosomal regions according to their association to survival. Over-representation analysis including 1-4 consecutive cytogenetic bands identified regions with increased expression for chromosome 5q12-14, and a very large region of chromosome 7 with the strongest signal at 7p15-13 among tumors from short-living patients. Reduced gene expression was identified at 4q26-32, 6p12-q15, 9p21-q32, and 11p14-11. We summarized mutation load in these regions by a combined mutation score that is statistical significantly associated to survival by analysis in the data sets used for identification of the regions. Furthermore, the prognostic value of the combined mutation score was validated in an independent large data set using death (P = 0.015) and recurrence (P = 0.002) as outcome. The combined mutation score is strongly associated to upregulation of several growth factor pathways.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19441089     DOI: 10.1002/gcc.20676

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  8 in total

1.  Genomic imbalances in esophageal carcinoma cell lines involve Wnt pathway genes.

Authors:  Jacqueline Brown; Hannelie Bothma; Robin Veale; Pascale Willem
Journal:  World J Gastroenterol       Date:  2011-06-28       Impact factor: 5.742

2.  Upregulated INHBA expression is associated with poor survival in gastric cancer.

Authors:  Quan Wang; Yu-Gang Wen; Da-Peng Li; Jun Xia; Chong-Zhi Zhou; Dong-Wang Yan; Hua-Mei Tang; Zhi-Hai Peng
Journal:  Med Oncol       Date:  2010-12-04       Impact factor: 3.064

3.  GINS2 Functions as a Key Gene in Lung Adenocarcinoma by WGCNA Co-Expression Network Analysis.

Authors:  Wen Tian; Xianglin Yang; He Yang; Baosen Zhou
Journal:  Onco Targets Ther       Date:  2020-07-08       Impact factor: 4.147

4.  Differential network analysis reveals the genome-wide landscape of estrogen receptor modulation in hormonal cancers.

Authors:  Tzu-Hung Hsiao; Yu-Chiao Chiu; Pei-Yin Hsu; Tzu-Pin Lu; Liang-Chuan Lai; Mong-Hsun Tsai; Tim H-M Huang; Eric Y Chuang; Yidong Chen
Journal:  Sci Rep       Date:  2016-03-14       Impact factor: 4.379

5.  GINS2 Is Downregulated in Peripheral Blood of Patients with Intervertebral Disk Degeneration and Promotes Proliferation and Migration of Nucleus Pulposus Cells.

Authors:  Haitao Jiang; Hailang Sun; Jian Dai; Cheng Zhang; Xiaoming Tang
Journal:  Comput Math Methods Med       Date:  2022-09-01       Impact factor: 2.809

6.  Association of Copy Number Variation Signature and Survival in Patients With Serous Ovarian Cancer.

Authors:  Ryon P Graf; Ramez Eskander; Leo Brueggeman; Dwayne G Stupack
Journal:  JAMA Netw Open       Date:  2021-06-01

7.  Overexpression of centromere protein K (CENPK) in ovarian cancer is correlated with poor patient survival and associated with predictive and prognostic relevance.

Authors:  Chi-Chen Huang; Ding-Yen Lin; Yi-Chao Lee; Wen-Chang Chang; Kuen-Haur Lee
Journal:  PeerJ       Date:  2015-11-05       Impact factor: 2.984

8.  RecQL4 helicase amplification is involved in human breast tumorigenesis.

Authors:  Hongbo Fang; Linghu Nie; Zhenfen Chi; Jing Liu; Dan Guo; Xuemei Lu; Tom K Hei; Adayabalam S Balajee; Yongliang Zhao
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.